AIM’s Promising New Ampligen Trial for Pancreatic Cancer
No quantitative efficacy data were disclosed, but AIM ImmunoTech reports positive progression-free survival, overall survival, and safety signals from...
eClinical Tech News
New Osstic™ Bone Filler Enters Clinical Trial for Fractures
No efficacy or safety outcomes have been reported yet. The development moves into humans with MHRA approval for a...
Alzheimer’s Study Results Were Foreseeable, Not Astonishing
A 20-year follow-up of the NIH-funded, 2,800-participant ACTIVE study reports that less than 23 hours of speed-of-processing training delivered...
Aprea’s WEE1 Inhibitor Shows Surging, Positive Trial Data
Aprea reported a 50% reduction in target lesions at first assessment and an 87% drop in CA-125 (362 to...
Cogent Highlights Bezuclastinib Summit Trial Data at AAAAI
Bezuclastinib delivered a mean −32.0-point reduction in total symptom score at 48 weeks in NonAdvanced systemic mastocytosis, a 56%...
First Patient Dosed in MindRank’s AI-Designed GLP-1 Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of its oral...
MindRank’s Breakthrough AI GLP-1 Drug Enters Phase III Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of MDR-001, an...
New Hope: Stem Cell Trial Improves Age-Related Frailty
In a Phase 2b randomized, dose-finding study of 148 ambulatory adults with aging-related frailty, intravenous laromestrocel improved six-minute walk...
Starton Doses First Patient in Phase 2a Myeloma Study
In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete...
Klothea Bio Launches mRNA Trial for Lifespan Extension
Klothea Bio has initiated a randomized, double-blind, placebo-controlled Phase 1b study of AKL003, an intravenous alpha Klotho mRNA therapeutic...